HIV vaccines: lessons learned and the way forward

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• An effective human immunodeficiency virus (HIV) vaccine remains a critical global health priority.
• Previous HIV vaccine trials have faced challenges in demonstrating efficacy.
• Understanding past trial outcomes is crucial for advancing vaccine development.

Purpose of the Study:

• To review lessons learned from five HIV vaccine trials (four failures, one modest success).
• To identify pathways for future HIV vaccine development based on trial experiences.
• To highlight the limitations of current models in predicting vaccine efficacy.

Main Methods:

• Review of data from four failed HIV vaccine trials and one partially successful trial (RV144).
• Analysis of vaccine-induced immune responses, including innate and adaptive immunity.
• Examination of limitations in laboratory and animal models for predicting clinical outcomes.

Main Results:

• The Merck Ad5 T-cell vaccine trial showed no efficacy and potentially increased HIV risk in men who have sex with men.
• The VaxGen gp120 vaccine was not efficacious in high-risk groups.
• The RV144 trial demonstrated 31% efficacy in heterosexuals using an ALVAC prime and gp120 boost regimen.
• All reviewed trials highlighted the inadequacy of current models to predict vaccine-induced immune responses and clinical efficacy.

Conclusions:

• Future HIV vaccine trials need to identify RV144-associated immune responses linked to protection.
• Enhancing the durability and level of protection is essential.
• Efficacy must be evaluated in diverse risk groups.
• Novel strategies, including heterologous prime-boost regimens and new immunogens, are needed to induce robust T-cell and antibody responses.
• Sustained commitment from scientists, governments, and communities is vital for HIV vaccine development.